Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.8752W HIGH $10.80
Volume
110.00
Value Traded
-
Short % Float
0%
Days to Cover
1.2
+25%Week
-94.37%5 Year
+459.47%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
10.07 M
EPS (TTM)
-8.57
P/E Ratio
-
Ent. Value
-
Total Shares
-
Float Shares
-
Insiders
0.00%
Institutions
0.00%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
ORGS Catalyst Timeline
Dated clinical, regulatory and corporate events for Orgenesis Inc.
Past FDA Catalysts and PDUFA Decisions
How ORGS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every ORGS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Safier Jacob10% Owner | Buy | 10,000 3,120,100 held | $0.58 | 06/24/2024 |
Hedge Fund 13F Activity
Hedge Funds invested in ORGS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ORGS for Q2 2026. | ||||
Ownership Trends
ORGS Short Interest
Shares sold short, counted twice a month.
0%
Short % of Float
of tradable shares sold short
5.3K
Shares Sold Short
0.0% vs prior count
1.2 Low
Days to Cover
trading days of normal volume to buy every short share back
4.3K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ORGS ranks across every disease it competes in
Competitive Position is a premium feature
See how ORGS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialORGS News
ORGS▼ -11.2%on this news
Orgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture Holdings
Orgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture Holdings Funding Aimed at Accelerating Rollout of Decentralized GERMANTOWN, MD - January 28, 2025 - Orgenesis Inc. (OTCQX: ORGS) ("Orgenesis" or the "Company"), a global biotech company working to
Read more →ORGS▼ -24.6%on this news
Orgenesis Announces Reverse Stock Split GERMANTOWN, MD
Announces Reverse Stock Split MD, September 23, 2024 - Orgenesis Inc. (Nasdaq:ORGS) ("Orgenesis" or the "Company") today announced that its Board of Directors has approved a 1-for-10 reverse stock split of the Company's common stock, par value $0.0001, which will be effective
Read more →ORGS▲ +12.6%on this news· ran to +23% by day 3
Orgenesis Inc. Announces $2.3 Million Private Placement GERMANTOWN, MD
Inc. Announces $2.3 Million Private Placement MD, March 4, 2024 - Orgenesis Inc. (NASDAQ: ORGS) ("Orgenesis" or the "Company"), a global leader in decentralized cell and gene therapies (CGTs), announced today that it has entered into a definitive securities purchase agreement w
Read more →ORGS▼ -10.5%on this news· ran to -28% by day 3
Orgenesis Inc. Announces Pricing of $1.1 Million Registered Direct Offering Germantown Maryland
Inc. Announces Pricing of $1.1 Million Registered Direct Offering Maryland, November 8, 2023 - Orgenesis Inc. ("Orgenesis") (Nasdaq: ORGS), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), announced today that it has entered into
Read more →ORGS▼ -11.8%on this news· ran to -26% by day 1
Orgenesis Announces Withdrawal of Proposed Public Offering Germantown, Maryland
Orgenesis Announces Withdrawal of Proposed Public Germantown, Maryland - October 30, 2023 - Orgenesis Inc. (NASDAQ: ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today announced that it has
Read more →ORGS▼ -32.4%on this news
Orgenesis Inc. Announces Pricing of $3.7 Million Registered Direct Offering GERMANTOWN, Md.
Inc. Announces Pricing of $3.7 Million Registered Direct Offering Md., February 23, 2023 (GLOBE NEWSWIRE) - Orgenesis, Inc. (Nasdaq: ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies, today announced
Read more →ORGSOrgenesis Inc. Announces $14.8 Million Private Placement GERMANTOWN, MD
Inc. Announces $14.8 Million Private Placement MD, March 31, 2022 - Orgenesis Inc. (NASDAQ: ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies, announced today that it has entered into a definitive secu
Read more →ORGSOrgenesis Reports Revenue Growth of 364% for 2021 and Provides Business Update Orgenesis to host conference call today at 12:00
Reports Revenue Growth of 364% for 2021 and Provides Business Update to host conference call today at 12:00 PM ET MD - March 30, 2022 - Orgenesis Inc. (NASDAQ: ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene
Read more →ORGSTranscript of video at https://www.youtube.com/watch?v=VsOu4UOjhMs: Orgenesis is a global biotech company working to unlock the full potential of cell and gene therapies (CGTs) in an affordable and accessible format at t
of video at https://www.youtube.com/watch?v=VsOu4UOjhMs: is a global biotech company working to unlock the full potential of cell and gene therapies (CGTs) in an affordable and accessible format at the point of care. CGTs are among the fastest growing sectors in medicine, but t
Read more →ORGSOrgenesis Provides Fiscal 2020 Year-End Results and Corporate Update; Expands POCare Therapeutic Pipeline, POCare Technologies, and POCare Network Revenue increases 96% to $7.7 million for 2020 Projects to more than doub
Provides Fiscal 2020 Year-End Results and Corporate Update; Expands POCare Therapeutic Pipeline, POCare Technologies, and POCare Network increases 96% to $7.7 million for 2020 to more than double in revenue for 2021 based on current contracts already in hand to host conferenc
Read more →ORGSThe information provided in each Item contained in this Exhibit is presented only in connection with the reporting changes described in the accompanying Current Report on Form 8-K. It does not reflect information, develo
information provided in each Item contained in this Exhibit is presented only in connection with the reporting changes described in the accompanying Current Report on Form 8-K. It does not reflect information, developments, or events occurring after March 9, 2020, the date on w
Read more →ORGSOrgenesis Announces Agreement to Acquire Koligo Therapeutics, a Leader in Personalized Cell Therapies Acquisition to support accelerated commercialization of Koligo's KYSLECEL , a personalized islet cell therapy availabl
Announces Agreement to Acquire Koligo Therapeutics, a Leader in Personalized Cell Therapies to support accelerated commercialization of Koligo's KYSLECEL , a personalized islet cell therapy available in the U.S. for chronic and recurrent acute pancreatitis to rapidly advance K
Read more →ORGSFiled by newsfilecorp.com
Orgenesis Inc. Announces $9.2 Million Private Placement GERMANTOWN, Md., January 21, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) ("Orgenesis" or the "Company"), a leading cell and gene therapy enabling company providing centralized CDMO manufacturing and development s
Read more →ORGSFiled by newsfilecorp.com Orgenesis First Quarter 2019 Revenue Increases 177% to a Record $7.3 Million Company Expands Point of Care Platform; Benefits from Growing Cell and Gene Therapy Market GERMANTOWN, MD
Orgenesis First Quarter 2019 Revenue Increases 177% to a Company Expands Point of Care Platform; Benefits from Growing Cell and Gene Therapy Market GERMANTOWN, MD May 9, 2019 Orgenesis Inc. (NASDAQ: ORGS) ( Orgenesis or the Company ), a developer, manufacturer and service pro
Read more →ORGSFiled by newsfilecorp.com Orgenesis Reports 73% Increase in Revenue for the Second Quarter of Fiscal 2018 CDMO segment achieves operating profit of $1.2 million GERMANTOWN, MD
Orgenesis Reports 73% Increase in Revenue Quarter of Fiscal 2018 CDMO segment achieves operating profit of $1.2 million GERMANTOWN, MD July 17, 2018 Orgenesis Inc. (Nasdaq:ORGS), a manufacturer, service provider and developer of advanced cell therapies, today reported financ
Read more →ORGSFiled by newsfilecorp.com Orgenesis Announces a Strategic Corporate Regrouping of its CDMO Activities Under the Global MaSTherCell Brand & Service Offerings Alignment MaSTherCell and Global CDMO Partners will be Presenti
Orgenesis Announces a Strategic Corporate Regrouping of its CDMO Activities Under the Global MaSTherCell Brand & Service Offerings MaSTherCell and Global CDMO Partners will be Presenting the New Global Branding at the Phacilitate Cell & Gene Therapy Meeting in Miami GERMANTOW
Read more →ORGSFiled by newsfilecorp.com For Immediate Release
ORGENESIS COMPLETES REVERSE STOCK SPLIT GERMANTOWN, MD November 16, 2017 Orgenesis Inc. (OTCQB: ORGS) ( Orgenesis or the Company ), a fully-integrated cell therapy and contract development and manufacturing company, today announced a reverse stock split of its shares of commo
Read more →ORGSFiled by newsfilecorp.com For Immediate Release Orgenesis Provides Update Regarding AIP Cell-Based Therapy for Type 1 Diabetes, MaSTherCell Cell Manufacturing Subsidiary and Overall Financial Condition GERMANTOWN, MD
Orgenesis Provides Update Regarding AIP Cell-Based Therapy for Type 1 Diabetes, MaSTherCell Cell Manufacturing Subsidiary and Overall GERMANTOWN, MD March 8, 2017 Orgenesis Inc. (OTCQB: ORGS), a vertically-integrated biopharmaceutical company with expertise and unique experi
Read more →ORGSFiled by newsfilecorp.com For Immediate Release ORGENESIS APPROVED FOR EURO 12.3 MILLION EUROPEAN GRANT FOR FURTHER DEVELOPMENT OF ITS TYPE 1
ORGENESIS APPROVED FOR EURO 12.3 MILLION EUROPEAN GRANT FOR DEVELOPMENT OF ITS TYPE 1 DIABETES PROGRAM GERMANTOWN, MD February 13, 2017 Orgenesis Inc. (OTCQB: ORGS), a fully-integrated cell therapy and contract development and manufacturing company, announced that its Belgian
Read more →ORGSFiled by newsfilecorp.com For Immediate Release Orgenesis to Collaborate with the Global Stem Cell & Regenerative Medicine Acceleration Center of Korea Seoul, South Korea
Orgenesis to Collaborate with the Global Stem Cell & Regenerative Medicine Acceleration Center of Korea Seoul, South Korea Apr. 7, 2015 Orgenesis Ltd., a wholly-owned subsidiary of Orgenesis Inc. (OTCQB: ORGS) a cell therapy and regenerative medicine company with a novel ther
Read more →About Orgenesis Inc.
Headquarters20271 Goldenrod Lane
Founded13-03-2012
BIOPHARMAWATCH ELITE
Trade the next ORGS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime